Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGN-75 + everolimus
- Development stage
- Unknown
- Lead developer
- Skagen
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
**SGN-75 + everolimus** is a combination investigational therapy consisting of SGN-75, an antibody-drug conjugate (ADC), and everolimus, an oral mTOR inhibitor. SGN-75 is composed of an anti-CD70 monoclonal antibody linked to monomethyl auristatin F (MMAF), a cytotoxic agent, by proprietary technology developed by Seattle Genetics (now Seagen). SGN-75 selectively targets CD70-expressing tumor cells, delivering the potent cytotoxic agent directly to these cells to spare non-target tissues. Everolimus, marketed as Afinitor, inhibits the mammalian target of rapamycin (mTOR), thereby blocking cell growth, proliferation, and angiogenesis in cancer cells. The combination is under investigation for treatment of CD70-positive metastatic renal cell carcinoma, particularly in patients who have progressed after tyrosine kinase inhibitor therapy.
- Brand names
- Afinitor
- Other names
- SGN-75 + everolimus
02
Targets
CD70 (Cluster of Differentiation 70)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on SGN-75 + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGN-75 + everolimus.